Skip to content
sellModerate cluster of 510b5-1 plan

Joseph H Wender sold $2.1M of IONS

director at IONIS PHARMACEUTICALS INC. 28,000 shares at an average of $74.02, traded Oct 30, 2025, filed Nov 3, 2025.

Warning score
45
Value
$2.1M
28,000 shares
Holdings after
64,035
-30% from before
From 52-week low
+191%
low $25.51, close $74.17
From 52-week high
0%
high $74.17, as of Oct 30, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $2.1M at market
    +25
  • Share of holdings sold
    Sold 30% of holdings
    +10
  • Cluster
    5 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IONSOct 9, 2026 · close 45.28
Since filing Nov 3, 2025: -38.5%SPY +15.2% · excess -53.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000874015-25-000272, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 30, 2025SOpen-market sale
Common Stockindirect: by Trust10b5-1
-2,484$72.19$179k89,551Nov 3, 2025
Oct 30, 2025SOpen-market sale
Common Stockindirect: by Trust10b5-1
-8,341$73.16$610k81,210Nov 3, 2025
Oct 30, 2025SOpen-market sale
Common Stockindirect: by Trust10b5-1
-5,975$73.85$441k75,235Nov 3, 2025
Oct 31, 2025SOpen-market sale
Common Stockindirect: by Trust10b5-1
-11,200$75.16$842k64,035Nov 3, 2025

Related signals

Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Joseph H Wender
director
$2.3M
28,000 shares
-44%
30Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Shannon L. Devers
EVP, Chief Human Resources Ofc
$1.4M
16,777 shares
-49%
39Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Joseph Klein III
director
$960k
12,000 shares
-300%
60Notable
IONSsell 6
IONIS PHARMACEUTICALS INC
Joan E Herman
director
$3.2M
44,000 shares
-76%
35Weak
IONSsell 510b5-1
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$609k
8,000 shares
-14%
40Moderate
IONSsell 510b5-1
IONIS PHARMACEUTICALS INC
Richard S Geary
EVP, Chief Development Officer
$2.6M
34,639 shares
-57%
40Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Richard S Geary
EVP, Chief Development Officer
$6.8M
90,929 shares
-80%
30Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Joseph Loscalzo
director
$1.2M
16,000 shares
-31%
30Weak
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$1.7M
23,900 shares
-35%
23Weak
IONSsell 810b5-1
IONIS PHARMACEUTICALS INC
Shannon L. Devers
EVP, Chief Human Resources Ofc
$531k
7,263 shares
-33%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph H Wender sold $2.1M of IONS | InsiderTell